日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia

伊克利普汀对血液学参数的影响:健康志愿者和伴有精神分裂症认知障碍患者的非临床研究和临床试验概述

Nagy, Peter; Fowler, Justin Corey; Rosenbrock, Holger; Tang, Wenbo; Fu, Eric; Fraser, Annie; Dursema, Holly; Schlichtiger, Julia; Desch, Michael; Gruenenfelder, Fredrik

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies

肾功能或肝功能损害对伊克利帕汀(BI 425809)药代动力学的影响:两项 I 期开放标签、非随机、单剂量、平行设计研究的结果

Choi, HeeJae; Madari, Shilpa; Daalman, Elmar; English, Brett A; Halabi, Atef; Hohl, Kathrin; Shatillo, Yury; Weidinger, Nathalie; Desch, Michael

Pre-Emptive Drug Safety Evaluation of Iclepertin (BI-425809) Using Real-World Data and Virtual Addition of This Medication to the Actual Drug Regimen of Individuals from Large Populations

利用真实世界数据和将该药物虚拟添加到来自大样本人群的实际用药方案中,对 Iclepertin (BI-425809) 进行预先药物安全性评估

Härtter, Sebastian; Michaud, Veronique; Smith, Matt K; Dow, Pamela; Condon, Gerald; Desch, Michael; Turgeon, Jacques

Evaluation of the Drug-Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach

评估 GlyT1 抑制剂 Iclepertin (BI 425809) 的药物相互作用潜力:基于生理药代动力学 (PBPK) 模型的方法

Matsson, Elin M; Desch, Michael; Nock, Valerie; Hanke, Nina

Assessing the Effect of Food on the Pharmacokinetics of Iclepertin in Healthy Volunteers: A Phase I, Open-Label, Randomised, Cross-over Trial

评估食物对健康志愿者体内伊克利帕汀药代动力学的影响:一项 I 期、开放标签、随机、交叉试验

Madari, Shilpa; Breithaupt-Groegler, Kerstin; English, Brett A; Hohl, Kathrin; Jungnik, Arvid; Desch, Michael

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia

开发新型 GlyT1 抑制剂 iclepertin (BI 425809) 用于治疗与精神分裂症相关的认知障碍

Rosenbrock, Holger; Desch, Michael; Wunderlich, Glen

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study

新型甘氨酸转运蛋白1抑制剂BI 425809与细胞色素P450和P-糖蛋白底物的药代动力学相互作用:体外分析和一项开放标签、单序列I期研究的结果

Desch, Michael; Schlecker, Christina; Hohl, Kathrin; Liesenfeld, Karl-Heinz; Chan, Tom; Müller, Fabian; Wunderlich, Glen; Keller, Sascha; Ishiguro, Naoki; Wind, Sven

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males

健康男性口服 BI 425809 或口服联合静脉注射微量示踪剂 [(14)C]-BI 425809 后,其绝对生物利用度、吸收、分布、代谢和排泄情况

Burkard, Ute; Desch, Michael; Shatillo, Yury; Wunderlich, Glen; Mack, Salome Rebecca; Schlecker, Christina; Teitelbaum, Aaron M; Liu, Pingrong; Chan, Tom S

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

细胞色素P450 3A4诱导和抑制对新型甘氨酸转运蛋白1抑制剂BI 425809药代动力学的影响

Desch, Michael; Wunderlich, Glen; Goettel, Markus; Goetz, Sophia; Liesenfeld, Karl-Heinz; Chan, Tom S; Rosenbrock, Holger; Sennewald, Regina; Link, Jasmin; Keller, Sascha; Wind, Sven

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

新型GlyT1抑制剂BI 425809的药代动力学和药效学评价:转化研究

Rosenbrock, Holger; Desch, Michael; Kleiner, Oliver; Dorner-Ciossek, Cornelia; Schmid, Bernhard; Keller, Sascha; Schlecker, Christina; Moschetti, Viktoria; Goetz, Sophia; Liesenfeld, Karl-Heinz; Fillon, Gwenaelle; Giovannini, Riccardo; Ramael, Steven; Wunderlich, Glen; Wind, Sven